구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Upifitimab rilsodotin (Upifitimab rilsodotin) Mersana Therapeutics·High Grade Serous Ovarian Cancer 1 trials |
|---|---|
Overview Program | Upifitimab rilsodotin |
Overview Company | Mersana Therapeutics |
Overview Modality | ANTIBODY |
Overview Target | High Grade Serous Ovarian Cancer |
Overview Indication | High Grade Serous Ovarian Cancer; Fallopian Tube Cancer |
Overview Phase | PHASE_3 |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Antibody-drug conjugates in gynecologic cancer: current landscape, clinical data, and emerging targets.. Antibody-drug conjugates (ADCs) are an emerging class of targeted therapies that combine monoclonal antibodies with potent cytotoxic payloads, demonstrating significant potential in the treatment of gynecologic malignancies. By selectively targeting tumor-associated antigens, ADCs enable precis… |
Clinical Safety signal | Antibody-drug conjugates in gynecologic cancer: current landscape, clinical data, and emerging targets.. Antibody-drug conjugates (ADCs) are an emerging class of targeted therapies that combine monoclonal antibodies with potent cytotoxic payloads, demonstrating significant potential in the treatment of gynecologic malignancies. By selectively targeting tumor-associated antigens, ADCs enable precis… |
Clinical Program phase | PHASE_3 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Upifitimab rilsodotin (Upifitimab rilsodotin) Mersana Therapeutics·High Grade Serous Ovarian Cancer 1 trials |
|---|---|
Overview Program | Upifitimab rilsodotin |
Overview Company | Mersana Therapeutics |
Overview Modality | ANTIBODY |
Overview Target | High Grade Serous Ovarian Cancer |
Overview Indication | High Grade Serous Ovarian Cancer; Fallopian Tube Cancer |
Overview Phase | PHASE_3 |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Antibody-drug conjugates in gynecologic cancer: current landscape, clinical data, and emerging targets.. Antibody-drug conjugates (ADCs) are an emerging class of targeted therapies that combine monoclonal antibodies with potent cytotoxic payloads, demonstrating significant potential in the treatment of gynecologic malignancies. By selectively targeting tumor-associated antigens, ADCs enable precis… |
Clinical Safety signal | Antibody-drug conjugates in gynecologic cancer: current landscape, clinical data, and emerging targets.. Antibody-drug conjugates (ADCs) are an emerging class of targeted therapies that combine monoclonal antibodies with potent cytotoxic payloads, demonstrating significant potential in the treatment of gynecologic malignancies. By selectively targeting tumor-associated antigens, ADCs enable precis… |
Clinical Program phase | PHASE_3 |
추천 비교
추천 비교